Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders

Inactive Publication Date: 2005-11-10
REPLIGEN CORP
View PDF21 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The present invention features a method for the treatment of neurological, immunological and other disorders in a patient. The method comprises the step of stimulating the secretion of pancreatic juices in the patient. In one embodiment, stimulating the secretion of pancreatic juices comprises the step of administering to the patient an effective amount of natural or synthetic secretin. The preferred method of the present invention is for the treatment of autistic spectrum disorder.
[0010] According to one method of administering secretin, the secretin is administered by infusion and the effective amount is generally 2 clinical units (CU) per kilogram (kg) of body weight given intravenously within 1 minute. In another method, the secretin is administered transdermally by applying a transdermal carrier substance, such as dimethyl sulfoxide (DMSO) to the skin, applying crystalline secretin in an effective amount onto the carrier substance, and rubbing the composition into the skin. One example of an effective amount of secretin administered transdermally includes about 15 CU of crystalline secretin.
[0011] Other methods of administering secretin include, but are not limited to, administering secretin transdermally with a gel, lotion or patch; administering secretin with a suppository; administrating secretin orally, as tablet, capsule or lozenge; administrating secretin by inhalation (e.g., as an aerosol) either through the mouth or the nose; and administering secretin using

Problems solved by technology

Many individuals with autism experience intestinal difficulties, often including the inability to digest gluten and casein.
Similar to autistic spectrum disorder, many other behavioral, neurological and immunological disorders have been equally difficult to understand and to effectively treat.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0018] When the patient was three years old, the secretin was administered by way of an infusion as part of an upper gastrointestinal endoscopy. The secretin was used in this diagnostic procedure at the request of the patient's parents, one of which is an inventor of the present invention. The secretin used in this procedure is known as Secretin-Ferring available from Ferring Laboratories, Inc., Suffern, N.Y. (See Appendix A). The secretin was dissolved in a 7.5 solution of sodium chloride and administered in a dosage of 2 clinical units (CU) per kilogram (kg) body weight by intravenous injection over one minute. (I.E. 30 IU IV for approximately 15 kilograms of body weight.)

[0019] Immediately after the administration of the secretin, the diagnostic testing revealed that the patient's pancreas responded, quite surprisingly, with an unusually large amount of pancreatic juice being released (approximately 10 ml / min compared to a usual rate of 1-2 ml / min). The diagnostic tests performe...

example 2

[0022] At the time of this treatment, the patient was about 4 years old. Secretin was administered transdermally using pharmaceutical grade dimethyl sulfoxide (DMSO) (generally 99.9% pure) available from Clinic Service Co., Box 2512, Hemet Calif. 92543. The secretin (Secretin-Ferring) was administered daily in a dosage of about 75 CU over a five day period (i.e., about 15 CU daily) For each treatment, about 4 drops of DMSO were placed onto the skin of the patient, about 15 CU of the crystalline secretin was placed onto the DMSO, and the composition was rubbed into the skin.

[0023] The administration of secretin transdermally on a daily basis in this way has resulted in even more dramatic and significant improvements in the patient. Within a period of about 6 months, the patient has progressed to spontaneous and conversational language. When the daily dose of secretin is stopped, the autistic behavioral symptoms return.

[0024] It is important to note that similar results have been se...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Levelaaaaaaaaaa
Body weightaaaaaaaaaa
Acoustic propertiesaaaaaaaaaa
Login to View More

Abstract

Secretin and secretin compositions are used for the treatment of autism and other neurological, behavioral and immunological disorders. The method includes administering an effective amount of secretin, such as Secretin-Ferring, to a patient. In one example, 2 clinical units (CU) of Secretin-Ferring was dissolved in a 7.5 ml solution of sodium chloride and was intravenously injected over 1 minute. In another example, secretin was administered transdermally by applying dimethyl sulfoxide (DMSO) to the patients skin and rubbing about 15 CU of Secretin-Ferring into the DMSO. Other methods and compositions for administering the effective amount of secretin include other transdermal carrier substances, such as gels, lotions, or patches; oral carriers, such as tablets, capsules, or lozenges; inhalation through the nose or mouth (e.g., as an aerosol); suppository forms of secretin and secretin compositions; and using acoustic waves to cause the secretin to penetrate the skin.

Description

RELATED APPLICATION [0001] This application claims the benefit of U.S. Provisional Application Ser. No. 60 / 088,575 filed Jun. 9, 1998, fully incorporated herein by reference, and is a continuation-in-part of U.S. patent application Ser. No. 09 / 080,631 filed May 18, 1998 and entitled Method For Assisting in Differential Diagnosis And Treatment Of Autistic Syndromes.FIELD OF THE INVENTION [0002] The present invention relates to methods and compositions for the treatment of neurological, behavioral and / or immunological disorders and more particularly, to a new medical use for the natural or synthetic hormone secretin in the treatment of autism and other neurological, behavioral and / or immunological disorders. BACKGROUND OF THE INVENTION [0003] Autism is a disabling neurological disorder that affects thousands of Americans and encompasses a number of subtypes, with various putative causes and few documented ameliorative treatments. The disorders of the autistic spectrum may be present a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K38/22A61K38/54A61K47/20A61P25/00A61P25/18A61P25/24A61P25/28A61P37/02A61P37/08A61P43/00
CPCA61K9/0014A61K38/2235G01N2800/38G01N2800/28A61K47/20A61P25/00A61P25/18A61P25/24A61P25/28A61P37/02A61P37/08A61P43/00
Inventor BECK, VICTORIARIMLAND, BERNARD
Owner REPLIGEN CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products